Martin Nicklasson (born 1955), Chairman
Chairman of the board of directors since 2012. M.Sc. Pharm. PhD and Associate Professor at the Faculty of Pharmacy, Uppsala University.
CEO at Orphan Biovitrum AB 2007-2010. Astra/AstraZeneca 1978–1989 and 1991–2007, among other responsible for global marketing and business development within AstraZeneca, and CEO at AstraZeneca Sweden AB. CEO at Astra Hässle AB and responsible for R&D at KABI.
Chairman of the board of directors of Farma Holding AS and board member of Pozen Inc., Oasmia AB, Biocrine AB and Denator AB among others. Member of the Royal Academy of Engineering Sciences (IVA). |
 |
Raymond G. Hill (born 1945)
B. Pharm., Ph.D., D.Sc., (Hon) F. Med. Sci. Visiting Professor at Bristol, Surrey, Imperial and Strathclyde Universities.
President Emeritus at the British Pharmacological Society, Council Member of the Academy of Medical Sciences and Non-Executive Director of Addex, Covagen and Karolinska Development.
Shareholding and holding of options in Orexo: Stock options entitling to 11,570 shares.
|
 |
Staffan Lindstrand (born 1962)
Director since 2002. M.Sc. in Engineering.
Partner of HealthCap and Director of the board of directors of inter alia HealthCap AB, Aerocrine AB, PulmonX Inc. and Technolas Perfect Vision GmbH.
Shareholding and holding of options in Orexo: 963 shares indirect.
|
 |
Scott Myers (born 1966)
BA in Biology and MBA in Finance.
More than 20 years of experience in the pharmaceutical and health care consulting industries. Extensive experience from Europe and US in the areas of marketing, sales, medical affairs, business development and market access.
CEO at Aerocrine, AB, and former VP, Head of European Mid-Markets at UCB, SA, a global biopharmaceutical company. Former as several senior positions at Johnson & Johnson including Senior Vice President and General Manager of McNeil Specialty Products. |
|
Kristina Schauman (born 1965)
Director since 2012. M.Sc. Business & Economics.
Former CFO at OMX, Carnegie, Apoteket AB among others. Group Treasurer at Investor AB.
Board member of Vasakronan AB and Apoteket Pension Trust. Board member and Chairman of the Audit committee of Apoteket AB and Member of the Advisory Board, Rädda Barnen Sweden.
Shareholding in Orexo: 10.000 shares. |
|
Michael Shalmi (born 1965)
Director since 2010. M.D., MBA.
Senior Partner in Novo A/S investment unit Novo Growth Equity.
Shareholding and holding of options in Orexo: Does not hold any shares in Orexo. |
|